Annovis Bio Inc. (NYSE: ANVS) announced that its President and CEO, Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. The presentation will focus on the scientific rationale for treating Alzheimer's disease as a multi-protein disorder, emphasizing the company's approach of simultaneously targeting multiple neurotoxic proteins with its lead drug candidate, buntanetap.
Buntanetap is currently in a pivotal Phase 3 clinical trial for Alzheimer's and Parkinson's diseases. Unlike traditional therapies that target a single protein, buntanetap inhibits the translation of several neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. This multi-pronged strategy aims to address the underlying causes of neurodegeneration rather than just symptoms.
The presentation at Fierce Biotech Week, a major industry event, underscores the growing interest in multi-target therapies for complex neurodegenerative conditions. Dr. Maccecchini's talk will delve into the scientific basis for this approach and highlight the potential of buntanetap to halt disease progression and improve cognitive and motor functions.
“We are excited to share our research at Fierce Biotech Week,” said Dr. Maccecchini. “Our data support the hypothesis that Alzheimer's is a multi-protein disorder, and buntanetap's ability to simultaneously reduce multiple toxic proteins could offer a more effective treatment option.”
Annovis Bio, headquartered in Malvern, Pennsylvania, is a Phase 3 clinical-stage biotechnology company dedicated to developing treatments for neurodegenerative diseases. The company's focus on buntanetap represents a shift from single-target to multi-target therapies, which could have significant implications for how Alzheimer's and Parkinson's are treated in the future.
The full press release detailing the announcement is available at https://ibn.fm/kZ2Z4. For more information about Annovis Bio, visit www.annovisbio.com.
